Topical alprostadil cream for the treatment of erectile dysfunction: a combined analysis of the phase II program

By Steidle C.   Padma-Nathan H.   Salem S.   Tayse N.   Thwing D.   Fendl J.   Yeager J.   Harning R.  

Urology, Vol. 60, Iss. 6, 2002-12 ,pp. : 1077-1082

Elsevier

Access to resources Recommend Favorite

Intracavernous alprostadil alfadex (EDEX/VIRIDAL) is effective and safe in patients with erectile dysfunction after failing sildenafil (Viagra)

By Shabsigh R.   Padma-Nathan H.   Gittleman M.   McMurray J.   Kaufman J.   Goldstein I.  

Urology, Vol. 55, Iss. 4, 2000-04 ,pp. : 477-480

Elsevier

Access to resources Recommend Favorite

Pain in Patients with Traumatic Spinal Cord Injury

By Celik Canan  

Journal of Musculoskeletal Pain, Vol. 21, Iss. 1, 2013-03 ,pp. : 53-57

Informa Healthcare

Access to resources Recommend Favorite

A double-blind, placebo-controlled, efficacy and safety study of topical gel formulation of 1% alprostadil (Topiglan) for the in-office treatment of erectile dysfunction

By Goldstein I.   Payton T.R.   Schechter P.J.  

Urology, Vol. 57, Iss. 2, 2001-02 ,pp. : 301-305

Elsevier

Access to resources Recommend Favorite

Intracavernous alprostadil alfadex is more efficacious, better tolerated, and preferred over intraurethral alprostadil plus optional ACTIS: a comparative, randomized, crossover, multicenter study - a multidimensional scale for assessment of erectile

By Shabsigh R.   Padma-Nathan H.   Gittleman M.   McMurray J.   Kaufman J.   Goldstein I.  

Urology, Vol. 55, Iss. 1, 2000-01 ,pp. : 109-113

Elsevier

Access to resources Recommend Favorite